https://pr.capitalpress.com/article/Oculis-Upsized-Loan-Facility-to-Access-up-to-CHF-100-million/688c74da60d1088d1814c225
Oculis Upsized Loan Facility to Access up to CHF 100 million Intrado
to accessoculisupsizedloanfacility
https://japan-neverland.com/veritas-oculis-les-investigations-sacrees-les-editions-pika-annoncent-un-nouveau-manga/
Veritas Oculis – Les Investigations Sacrées – Les éditions Pika Annoncent Un Nouveau Manga - Japan...
Apr 28, 2026 - Il y a quelques jours, les éditions Pika ont annoncé l’arrivée dans leur catalogue du manga Veritas Oculis – Les investigations sacrées de You Asami, adapté du...
veritasoculislesinvestigationspika
https://www.smbworldreport.com/article/946586019-oculis-joins-the-national-multiple-sclerosis-society-s-campaign-to-end-ms
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS | SMB World Report
SMB World Report is an online news publication focusing on sme/smb: Get your daily news on small business
the nationalmultiple sclerosisworld reportoculisjoins
https://www.nasdaq.com/market-activity/stocks/ocs/financials
Oculis Holding AG Ordinary shares (OCS) Financials | Nasdaq
Find the latest Oculis Holding AG Ordinary shares (OCS) annual income statements, balance sheets, financial statements, ratios, and cash flow data at...
ordinary sharesoculisholdingocsfinancials
https://www.marketinout.com/stock/ocs
Oculis Holding AG (OCS) Quotes and Fundamentals
Oculis Holding AG (OCS) Quotes, Fundamentals, Technicals, Relative Strength, Financial Ratios, and Dividends
oculisholdingocsquotesfundamentals
https://www.djiboutipoliticaltimes.com/article/921689748-investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-oculis-holding-ag-ocs
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG...
on behalf oflaw firminvestoralertpomerantz
https://www.clinicaltrialsarena.com/news/oculis-first-patient-eye-drops/
Oculis enrols first patient in trial of its OCS-01 eye drops
Aug 3, 2023 - Oculis has enrolled the first patient in its investigator-initiated LEOPARD trial of OCS-01 eye drops to treat cystoid macular oedema (CME).
eye dropsoculisenrolsfirstpatient
https://www.dailyhealthcarestlucia.com/article/897317527-oculis-reports-q4-and-full-year-2025-financial-results-and-provides-company-update
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update | Daily...
financial resultscompany updateoculisreportsfull
https://www.optometrytimes.com/view/oculis-releases-positive-topline-results-from-phase-2-acuity-trial-evaluating-ocs-05-in-acute-optic-neuritis
Oculis releases positive topline results from phase 2 ACUITY trial evaluating OCS-05 in acute optic...
Oct 10, 2026 - The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).
oculisreleasespositivetoplineresults
https://wellnessfocuscaymanislands.com/article/897317527-oculis-reports-q4-and-full-year-2025-financial-results-and-provides-company-update
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update | Wellness Focus...
financial resultscompany updateoculisreportsfull
https://www.icelandbusinesstimes.com/article/946586019-oculis-joins-the-national-multiple-sclerosis-society-s-campaign-to-end-ms
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS | Iceland Business Times
the nationalmultiple sclerosisbusiness timesoculisjoins